JP2025516264A - 多重化t細胞受容体組成物、その併用療法、及び使用 - Google Patents
多重化t細胞受容体組成物、その併用療法、及び使用 Download PDFInfo
- Publication number
- JP2025516264A JP2025516264A JP2024564522A JP2024564522A JP2025516264A JP 2025516264 A JP2025516264 A JP 2025516264A JP 2024564522 A JP2024564522 A JP 2024564522A JP 2024564522 A JP2024564522 A JP 2024564522A JP 2025516264 A JP2025516264 A JP 2025516264A
- Authority
- JP
- Japan
- Prior art keywords
- hla
- tcr
- cell
- cells
- target
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4271—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4268—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/427—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—DNA viruses
- C07K16/084—Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
- A61K2239/29—Multispecific CARs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Data Exchanges In Wide-Area Networks (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263337522P | 2022-05-02 | 2022-05-02 | |
| US63/337,522 | 2022-05-02 | ||
| US202263342451P | 2022-05-16 | 2022-05-16 | |
| US63/342,451 | 2022-05-16 | ||
| US202263413553P | 2022-10-05 | 2022-10-05 | |
| US63/413,553 | 2022-10-05 | ||
| US202263423269P | 2022-11-07 | 2022-11-07 | |
| US63/423,269 | 2022-11-07 | ||
| PCT/US2023/020338 WO2023215183A1 (en) | 2022-05-02 | 2023-04-28 | Multiplexed t cell receptor compositions, combination therapies, and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025516264A true JP2025516264A (ja) | 2025-05-27 |
| JP2025516264A5 JP2025516264A5 (cg-RX-API-DMAC7.html) | 2026-05-13 |
Family
ID=88646870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024564522A Pending JP2025516264A (ja) | 2022-05-02 | 2023-04-28 | 多重化t細胞受容体組成物、その併用療法、及び使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250288675A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4519305A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025516264A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250006149A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119487060A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023265422A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3248253A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2024016274A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL316250A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024013482A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202406569A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023215183A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2024005746A (es) * | 2021-11-10 | 2024-07-19 | Tscan Therapeutics Inc | Peptidos inmunogenicos magea1, proteinas de union que reconocen peptidos inmunogenicos magea1, y usos de estos. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005113595A2 (en) * | 2004-05-19 | 2005-12-01 | Avidex Ltd | High affinity ny-eso t cell receptor |
| ES2635335T3 (es) * | 2010-09-20 | 2017-10-03 | Biontech Cell & Gene Therapies Gmbh | Receptores de células T específicos de antígeno y epítopos de células T |
| NZ741124A (en) * | 2012-07-27 | 2019-11-29 | Univ Illinois | Engineering t-cell receptors |
| JP6895975B2 (ja) * | 2016-01-06 | 2021-06-30 | ヘルス リサーチ インコーポレイテッドHealth Research, Inc. | 組換えt細胞受容体を含む組成物及びライブラリー並びに組換えt細胞受容体を使用する方法 |
| KR20190062505A (ko) * | 2016-10-03 | 2019-06-05 | 주노 쎄러퓨티크스 인코퍼레이티드 | Hpv-특이적 결합 분자 |
| JP7289028B2 (ja) * | 2018-09-05 | 2023-06-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 複数の主要組織適合遺伝子複合体分子に制限したny-eso-1-特異的t細胞受容体の組成物 |
| WO2020167957A1 (en) * | 2019-02-12 | 2020-08-20 | Board Of Regents, The University Of Texas System | High affinity engineered t-cell receptors targeting cmv infected cells |
| DE102019121007A1 (de) * | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| EP4010377A4 (en) * | 2019-08-09 | 2023-09-06 | A2 Biotherapeutics, Inc. | CELL SURFACE RECEPTORS THAT RESPOND TO LOSS OF HETEROZYGOSIS |
-
2023
- 2023-04-28 EP EP23799850.5A patent/EP4519305A4/en active Pending
- 2023-04-28 US US18/860,341 patent/US20250288675A1/en active Pending
- 2023-04-28 AU AU2023265422A patent/AU2023265422A1/en active Pending
- 2023-04-28 KR KR1020247038208A patent/KR20250006149A/ko active Pending
- 2023-04-28 WO PCT/US2023/020338 patent/WO2023215183A1/en not_active Ceased
- 2023-04-28 CN CN202380051389.XA patent/CN119487060A/zh active Pending
- 2023-04-28 CA CA3248253A patent/CA3248253A1/en active Pending
- 2023-04-28 TW TW112116024A patent/TW202406569A/zh unknown
- 2023-04-28 JP JP2024564522A patent/JP2025516264A/ja active Pending
- 2023-04-28 IL IL316250A patent/IL316250A/en unknown
-
2024
- 2024-10-31 MX MX2024013482A patent/MX2024013482A/es unknown
- 2024-11-28 CO CONC2024/0016274A patent/CO2024016274A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4519305A1 (en) | 2025-03-12 |
| KR20250006149A (ko) | 2025-01-10 |
| IL316250A (en) | 2024-12-01 |
| CN119487060A (zh) | 2025-02-18 |
| EP4519305A4 (en) | 2026-05-06 |
| TW202406569A (zh) | 2024-02-16 |
| WO2023215183A1 (en) | 2023-11-09 |
| CA3248253A1 (en) | 2023-11-09 |
| US20250288675A1 (en) | 2025-09-18 |
| CO2024016274A2 (es) | 2024-12-09 |
| AU2023265422A1 (en) | 2024-10-24 |
| MX2024013482A (es) | 2024-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7470640B2 (ja) | T細胞を製造する方法 | |
| EP3310805B1 (en) | Pd-1-cd28 fusion proteins and their use in medicine | |
| JP2023109921A (ja) | 改変された多能性幹細胞並びに製造方法及び使用方法 | |
| JP7491532B2 (ja) | HvG疾患の処置における使用のためのCAR | |
| US20190119350A1 (en) | Ny-eso-1 specific tcrs and methods of use thereof | |
| KR20210057730A (ko) | 조작 세포 및 이의 조성물 생성 방법 | |
| KR20250096881A (ko) | 유전자 조작된 세포를 제조하기 위한 방법 및 조성물 | |
| JP6580579B2 (ja) | T細胞受容体を発現する細胞を生産する方法および組成物 | |
| KR20190037243A (ko) | 면역치료를 위한 티 세포 조성물 | |
| JP7760524B2 (ja) | 改善されたt細胞製造プロセス | |
| CN110139873A (zh) | Hpv特异性结合分子 | |
| US20240270813A1 (en) | T CELL RECEPTORS (TCRs) TARGETING MINOR HISTOCOMPATIBILITY ANTIGEN HA-1 | |
| US20250288675A1 (en) | Multiplexed t cell receptor compositions, combination therapies, and uses thereof | |
| US20240000834A1 (en) | Ras mutant epitope peptide and t cell receptor recognizing ras mutant | |
| CN111234004B (zh) | 识别wt1抗原短肽的t细胞受体及其应用 | |
| CN118909085A (zh) | 识别wt1抗原短肽的t细胞受体(tcr)、多价tcr的复合物、药物组合物及用途 | |
| RU2795454C2 (ru) | Способы и композиции для получения генно-инженерных клеток | |
| WO2026055433A1 (en) | Expansion of tumor-reactive t cells using anti-cd28 antibodies | |
| HK40064520A (en) | Pd1-cd28 fusion proteins and their use in medicine | |
| WO2024243807A1 (zh) | 靶向ny-eso-1的高亲和力t细胞受体及其应用 | |
| CN118725080A (zh) | 识别肿瘤相关抗原的tcr分子及其用途 | |
| HK40063050B (en) | Car for use in the treatment of hvg disease | |
| HK40063050A (en) | Car for use in the treatment of hvg disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260428 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260428 |